Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01193517 · ClinicalTrials.gov registry record · Phase 1
Azacitidine and CAPOX in Metastatic Colorectal Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01193517: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01193517 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01193517, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The goal of the Phase I portion of this study is to find the highest tolerable dose of azacitidine combined with capecitabine and oxaliplatin (CAPOX) that can be given to patients with metastatic colorectal cancer. The goal of the Phase II portion of this study is to learn if azacitidine, given in combination with CAPOX, can help to control metastatic colorectal cancer. The safety of this drug combination will also be studied.
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
- DRUG Azacitidine
- DRUG Azacitidine MTD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01193517
The ClinicalTrials.gov registry entry for NCT01193517 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Capecitabine is the first listed.
NCT01193517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01193517 about?
NCT01193517 is a clinical study titled "Azacitidine and CAPOX in Metastatic Colorectal Cancer". The goal of the Phase I portion of this study is to find the highest tolerable dose of azacitidine combined with capecitabine and oxaliplatin (CAPOX) that can be given to patients with metastatic colorectal cancer. The goal of the Phase II portion of this study is to learn if azacitidine, given in ...
What is the current status of trial NCT01193517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2010-08. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01193517?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG), Azacitidine (DRUG), Azacitidine MTD (DRUG).
Who is sponsoring clinical trial NCT01193517?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.